These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 7863274)
41. Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. Kimura M; Tokuda Y; Oshiawa H; Yoshida K; Utsunomiya M; Kobayashi T; Deshpande GA; Matsui K; Kishimoto M J Rheumatol; 2012 Jan; 39(1):148-53. PubMed ID: 22174210 [TBL] [Abstract][Full Text] [Related]
42. [Serum amyloid A as a useful index of disease activity in polymyalgia rheumatica]. Yamane T; Yamauchi H; Abe N; Torio N; Shimada R; Senba T; Imaizumi Y; Nomura T Ryumachi; 2003 Jun; 43(3):544-8. PubMed ID: 12910963 [TBL] [Abstract][Full Text] [Related]
43. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Macchioni P; Boiardi L; Catanoso M; Pulsatelli L; Pipitone N; Meliconi R; Salvarani C Semin Arthritis Rheum; 2013 Aug; 43(1):113-8. PubMed ID: 23433960 [TBL] [Abstract][Full Text] [Related]
52. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. Cleuziou C; Binard A; De Bandt M; Berthelot JM; Saraux A J Rheumatol; 2012 Feb; 39(2):310-3. PubMed ID: 22174199 [TBL] [Abstract][Full Text] [Related]
53. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627 [TBL] [Abstract][Full Text] [Related]
54. Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of steroid treatment. Macchioni P; Boiardi L; Meliconi R; Salvarani C; Grazia Uguccioni M; Rossi F; Pulsatelli L; Facchini A J Rheumatol; 1994 Oct; 21(10):1860-4. PubMed ID: 7837151 [TBL] [Abstract][Full Text] [Related]
55. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. Palard-Novello X; Querellou S; Gouillou M; Saraux A; Marhadour T; Garrigues F; Abgral R; Salaün PY; Devauchelle-Pensec V Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):773-9. PubMed ID: 26753600 [TBL] [Abstract][Full Text] [Related]
56. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Kyle V; Hazleman BL Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975 [TBL] [Abstract][Full Text] [Related]
57. Favorable role of interleukin 10 in patients with polymyalgia rheumatica. Straub RH; Herfarth HH; Rinkes B; Konecna L; Glück T; von Landenberg P; Georgi J; Helmke K; Schölmerich J; Vaith P; Lang B J Rheumatol; 1999 Jun; 26(6):1318-25. PubMed ID: 10381050 [TBL] [Abstract][Full Text] [Related]
59. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Lee JH; Choi ST; Kim JS; Yoon BY; Kwok SK; Kim HS; Kim YS; Song JS; Lee SH; Kim HR Rheumatol Int; 2013 Jun; 33(6):1475-80. PubMed ID: 23184033 [TBL] [Abstract][Full Text] [Related]
60. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. Ma X; Yang F; Wu J; Xu B; Jiang M; Sun Y; Sun C; Yu Y; Xu D; Xiao L; Ren C; Chen C; Ye Z; Liang J; Lin J; Chen W PLoS Med; 2023 Jun; 20(6):e1004249. PubMed ID: 37384596 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]